Revvity (RVTY)
NYSE:RVTY
Want to see RVTY full AI Analyst Report?
RVTY Stock Chart & Stats
$93.96
-$0.88(-0.75%)
At close: 4:00 PM EST
$93.96
-$0.88(-0.75%)
Day’s Range― - ―
52-Week Range$81.36 - $118.30
Previous CloseN/A
Volume176.09K
Average Volume (3M)934.14K
Market Cap
$9.70B
Enterprise Value$12.30B
Total Cash (Recent Filing)$919.86M
Total Debt (Recent Filing)$3.52B
Price to Earnings (P/E)27.9
Beta0.93
Next Earnings
May 05, 2026EPS Estimate
1.02Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)1.70
Shares Outstanding111,803,330
10 Day Avg. Volume819,928
30 Day Avg. Volume934,140
Financial Highlights & Ratios
PEG Ratio-3.32
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue4.31
Enterprise Value/Gross Profit8.58
Enterprise Value/Ebitda16.06
Forecast
1Y Price Target
$107.67Price Target Upside14.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)5.39
Revenue Forecast (FY)$2.98B
Bulls Say, Bears Say
Bulls Say
Cost-reduction Program Driving MarginsAnalyst highlights that a large cost-reduction program should drive margin expansion as cost savings fully phase in, improving profitability prospects.
Preclinical And Diagnostic Demand RecoveryAnalyst notes emerging recovery in preclinical and biotech demand along with strengthening diagnostic testing outside China, which could support revenue growth.
Revenue Guidance And ValuationAnalyst observes organic revenue guidance modestly exceeds external expectations and regards the stock's valuation as attractive relative to anticipated growth and margin improvement, enhancing risk/reward appeal.
Bears Say
Conservative China Expectations And Excluded Product BenefitsAnalyst notes management's conservative stance on China diagnostic expectations and the exclusion of potential software launch benefits from guidance, which limits upside in the outlook.
Mixed Quarterly Report Creating Outlook UncertaintyAnalyst warns that multiple offsetting factors in the quarterly report and guidance make the outlook unclear despite clean headline results, weighing on investor confidence.
Reporting-period Timing Effects And Margin PressureAnalyst points out that a reporting-period timing effect may inflate reported sales while compressing margins initially, implying the need for substantial margin recovery later.
Revvity News
RVTY FAQ
What was Revvity’s price range in the past 12 months?
Revvity lowest stock price was $81.36 and its highest was $118.30 in the past 12 months.
What is Revvity’s market cap?
Revvity’s market cap is $9.70B.
When is Revvity’s upcoming earnings report date?
Revvity’s upcoming earnings report date is May 05, 2026 which is in 9 days.
How were Revvity’s earnings last quarter?
Revvity released its earnings results on Feb 02, 2026. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.13.
Is Revvity overvalued?
According to Wall Street analysts Revvity’s price is currently Undervalued.
Does Revvity pay dividends?
Revvity pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 0.29%. See more information on Revvity dividends here
What is Revvity’s EPS estimate?
Revvity’s EPS estimate is 1.02.
How many shares outstanding does Revvity have?
Revvity has 111,803,330 shares outstanding.
What happened to Revvity’s price movement after its last earnings report?
Revvity reported an EPS of $1.7 in its last earnings report, beating expectations of $1.57. Following the earnings report the stock price went down -1.571%.
Which hedge fund is a major shareholder of Revvity?
Currently, no hedge funds are holding shares in RVTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$107.67 (14.59% Upside)
$107.67 (14.59% Upside)
Blogger Sentiment
Bullish
RVTY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 133.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.62%
12-Months-Change
Fundamentals
Return on Equity
3.24%
Trailing 12-Months
Asset Growth
-1.81%
Trailing 12-Months
Company Description
Revvity
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
RVTY Company Deck
RVTY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear operational resilience—EPS and cash flow beats, strong diagnostics and software momentum, major share repurchases, and strategic AI/software initiatives—offset by persistent end-market softness, China diagnostic weakness, margin pressure and a conservative 2026 growth outlook. Achievements (guidance beat, FCF strength, software traction, ACD acquisition, Signals Synthetica launch) are balanced by notable challenges (modest organic growth guidance, China DRG impacts, near-term margin headwinds, rising below-the-line costs), resulting in a cautious but constructive tone.View all RVTY earnings summariesRVTY Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
$107.67
▲(14.59% Upside)